Expanding the Scope of Treatment: One Solution for Many Mutations

Current therapies for people living with cancer target a limited number of oncogenic mutations. Increasing use of liquid biopsies and next generation sequencing is revealing a large number of oncogenic alterations for which no therapies exist. Our MasterKey approach targets broad families of oncogenic mutations, with the potential to benefit large patient populations with limited treatment options. We are advancing oral therapies designed to give patients the opportunity for a longer, healthier, active life.

Our MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. Our efforts are focused on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Our mission is to provide people living with cancer the opportunity to experience longer, healthier, and more active lives. We support patient advocacy groups focusing on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Cancer is a complex and ever-evolving disease, yet current targeted therapies address a limited subset of oncogenic mutations. Our MasterKey approach aims to expand the addressable patient population by offering one solution for many mutations.